Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/EUCTR2008-003003-31-ES
EUCTR2008-003003-31-ESActive, not recruitingNot Applicable

Terapia de radiación y simultáneo (concurrente) más Temsirolimus coadyuvante (CCI-779) contra irradiación chimio con Temozolomide para glioblastoma recientemente diagnosticado sin methylation del promotor de gen MGMT - un multicentro randomizado, open-label, una fase II estudio

EORTC Headquarters0 sites108 target enrollmentStarted: July 29, 2009Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Drugs

Trial Snapshot

Phase
Not Applicable
Status
Active, not recruiting
Sponsor
Enrollment
108
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Sex
All

Inclusion Criteria

  • •?Present with newly diagnosed histologically proven supratentorial GBM (World Health Organization (WHO) grade IV). The histological diagnosis can be obtained either from an open brain biopsy or from a neurosurgical resection of the tumor.
  • •?Patients must be at least 18 years of age.
  • •?Estimated life expectancy of at least 12 weeks.
  • •?Tumor tissue specimens (paraffin-embedded and/or frozen) from the GBM surgery or open biopsy must be available for central pathology review, MGMT status determination and exploratory analysis of PI3-K/Akt/mTOR targets (P70S6K).
  • •?A 25 ml EDTA blood sample is also required.
  • •?WHO-ECOG Performance Status of ? 2.
  • •?Clinically normal cardiac function without history of ischemic heart disease in the past 6 months and normal 12-lead electrocardiogram (ECG); no history of stroke.
  • •?Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial.
  • •?Patients of childbearing/ reproductive potential should use highly effective method of birth control as defined by the investigator. For example those which result in a low failure rate (i.e. less than 1% per year) when used consistently and correctly such as implants, injectables, combined oral contraceptives, some IDUs, sexual abstinence or vasectomised partner. For subjects using a hormonal contraceptive method, information regarding the product under evaluation and its potential effect on contraceptives should be addressed. Women with childbearing potential must have a negative serum pregnancy test (?-HCG) ? 14 days prior to registration and can not be breastfeeding.
  • •?Before patient registration, written informed consent must be given according to ICH/GCP, and national/local regulations.
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range
  • •F.1.3 Elderly (>=65 years) yes
  • •F.1.3.1 Number of subjects for this age range

Exclusion Criteria

  • •Patients will be excluded from the study if they meet any of the following criteria:
  • •?Have had a prior malignancy within the last 5 years (other than adequately treated carcinoma in situ of the cervix, or non-melanoma skin cancer, with no subsequent evidence of recurrence).
  • •?Having undergone only a stereotactic biopsy (open biopsy is allowed as ensuring sufficient tumor tissue yield).
  • •?Unable to undergo Gd MRI.
  • •?Have had chemotherapy within the last 5 years
  • •?Prior chemotherapy for a brain tumor
  • •?Prior RT of the head
  • •?Are receiving concurrent administration of any other antitumor therapy
  • •?Are using enzyme inducing anti convulsivants (in particular carbamazepine, phenobarbital and phenytoine) and are unable to discontinue use of these agents. Or any other strong inducers or inhibitors of CYP3A4.
  • •?Planned surgery for other diseases (for example, dental extraction)
  • •?Placement of Gliadel® wafer at surgery
  • •?Have a serious concomitant systemic disorder (for example, active infection including HIV, or cardiac disease) that, in the opinion of the investigator, would compromise the patient?s ability to adhere to the protocol. Patients with a QTc prolongation >450/470 msec (males/females) and patients who have a congenital long-QT-syndrome in their own or family medical history should be excluded, at the investigator?s discretion.
  • •?Known hypersensitivity to the study treatment
  • •?Current alcohol dependence or drug abuse
  • •?Legal incapacity or limited legal capacity
  • •?Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of registration

Investigators

Sponsor
EORTC Headquarters

Similar Trials

Completed
Not Applicable
Combination therapy of radiation and intratumoral directo injection of dendritic cells for advanced esophageal cancer, a phase I study.Esophageal cancer
JPRN-UMIN000011079Chiba University6
Active, not recruiting
Not Applicable
Radiation therapy and concurrent plus adjuvant Temsirolimus (CCI-779) versus chemo-irradiation with Temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter – a randomized multicenter, open-label, Phase II studypatients with newly diagnosed glioblastoma (GBM) without methylation of the DNA-repair enzyme O6-methylguanin-DNA-methyltransferase (MGMT) gene promoterMedDRA version: 9.1Level: LLTClassification code 10006153Term: Brain tumor
EUCTR2008-003003-31-NLEORTC Headquarters108
Active, not recruiting
Not Applicable
Radiation therapy and concurrent plus adjuvant Temsirolimus (CCI-779) versus chemo-irradiation with Temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter – a randomized multicenter, open-label, Phase II studypatients with newly diagnosed glioblastoma (GBM) without methylation of the DNA-repair enzyme O6-methylguanin-DNA-methyltransferase (MGMT) gene promoterMedDRA version: 9.1Level: LLTClassification code 10006153Term: Brain tumor
EUCTR2008-003003-31-ATEORTC Headquarters108
Active, not recruiting
Not Applicable
Radiation therapy and concurrent plus adjuvant Temsirolimus (CCI-779) versus chemo-irradiation with Temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter a randomized multicenter, open-label, Phase II study. - NDpatients with newly diagnosed glioblastoma without methylation of the MGMT gene promotorMedDRA version: 12.0Level: LLTClassification code 10018336Term: Glioblastoma
EUCTR2008-003003-31-ITE.O.R.T.C. - EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER108
Active, not recruiting
Not Applicable
Radiation therapy and concurrent plus adjuvant Temsirolimus (CCI-779) versus chemo-irradiation with Temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter – a randomized multicenter, open-label, Phase II studypatients with newly diagnosed glioblastoma (GBM) without methylation of the DNA-repair enzyme O6-methylguanin-DNA-methyltransferase (MGMT) gene promoterMedDRA version: 13.1Level: LLTClassification code 10006153Term: Brain tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2008-003003-31-DEEORTC Headquarters108